A clinical study to see the effect of an Ayurvedic formulation in the treatment of Conjunctivitis.

Clinical Evaluation of Mahatriphaladya Ghrita in the Management of Allergic Conjunctivitis. - ACT- AC-2010

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/01/002375

Enrollment

150

Registered

2012-01-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Allergic Conjunctivitis

Interventions

Intervention1: Maha Triphaladya Ghrita: Dose â?? 15 ml twice daily Dosage form - Ghee Route of Administration â?? oral Time of Administration-Twice a day before food Anupana-Lukewarm Water Packing

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex aged between 16-35years. 2. Patients presenting with signs and symptoms of Allergic Conjunctivitis. 3. Willing and able to participate for 16 weeks.

Exclusion criteria

Exclusion criteria: 1. Patients having complications like marginal corneal ulcer, dacryocystitis, trachoma, kerato - conjunctivitis, Infective conjunctivitis, etc. 2. Patients having genetic predisposition to allergy. 3. Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT > 2 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.2mg/dl), uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or other concurrent severe disease. 4. Patients with poorly controlled Diabetes Mellitus (HbA1c > 10%) 5. Patients with poorly controlled Hypertension ( > 160 / 100 mm Hg) 6. Pregnant / lactating females 7. Patients on steroids, oral contraceptive pills or estrogen replacement therapy. 8. Smokers/Alcoholics and/or drug abusers 9. Patients with evidence of malignancy 10. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro- Endocrinal disorders, etc.) 11. H/o hypersensitivity to the trial drug or any of its ingredients. 12. Patients who have completed participation in any other clinical trial during the past six (06) months. 13. Any other condition which the P.I. thinks may jeopardize the study.

Design outcomes

Primary

Measure	Time frame
ï?? Symptomatic improvement.Timepoint: At Baseline, 14th day-28th day-42nd day-56th day-70th day-84th day and at the end of follow up after 16th week.	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Pradeep Dua

Central Council for Research in Ayurvedic Sciences (CCRAS)

duadrpradeep@gmail.com011-28525831

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026